Abstract: The invention relates to therapeutic uses of isolated fractions of mastic gum for treating optic neuropathy. More particularly, the invention relates to methods of treating optic neuropathy conditions using compositions comprising isolated fractions of mastic gum.

Abstract: The present invention is directed to tissue sealant compositions comprising: a multi-arm reactive polyethylene glycol polymer having at least 3 electrophilic groups; albumin; a buffer; water; and entrained gas as bubbles; wherein concentration of albumin in a liquid component of the sealant is within range of 50-200 mg/ml; and wherein concentration of multi-arm PEG in said liquid component of the sealant is within range of 25-100 mg/mL.

Abstract: The invention provides a colon cleansing solution comprising: a) 300 to 800 mmol per litre ascorbate anion provided by a mixture of: (i) ascorbic acid and (ii) one or more salts of ascorbic acid the components (i) and (ii) being present in a molar ratio of from 1:4.5 to 1:7.0; and b) 10 to 200 g per litre polyethylene glycol. The invention also provides methods an kits associated with, or making use of the solutions, and compositions for the preparation of the solutions.

Abstract: A package for delivering a single-dose product includes a softgel capsule which is comprised of at least one gelling agent selected from protein-based gelling agents and polysaccharide-based gelling agents. The capsule shell includes one or more areas of reduced thickness that are preferentially ruptured by exertion of a compressive force on the softgel capsule to create an opening in the capsule shell through which the fill composition can be delivered by spraying or squeezing. A method for manufacturing the softgel capsule having one or more areas of reduced shell thickness is also described.

Abstract: The present invention provides a method for preparing an injectable thermosensitive hydrogel for preventing adhesion including mixing methyl cellulose, polyethylene glycol, oxidized cellulose nanofibers and carboxymethyl cellulose. The injectable thermosensitive hydrogel for preventing adhesion is a sol at a low temperature and induces rapid gelation upon in vivo implantation due to thermosensitivity. In addition, the hydrogel can be rapidly changed into physical hydrogel without separate additives or chemical reaction during in vivo condition. In addition, the injectable thermosensitive hydrogel for preventing adhesion exhibits excellent biodegradability and biocompatibility, has no cytotoxicity, inhibits in vitro migration of rat bone marrow mesenchymal stem cells (rBMSCs), and exhibits anti-adhesion efficacy in a rat model of sidewall defect-cecum abrasion in vivo, thus being useful as an effective anti-adhesive agent.

Abstract: A water-based virucidal composition suitable for disinfecting a surface contaminated with non-enveloped virus is set forth, wherein the composition comprises alkylpolyglycoside surfactant in an amount of 0.1-5 wt. %, amineoxide surfactant in an amount of 0.1-5 wt. %, wherein the amineoxide is a compound of the formula R1R2R3N+O?, wherein R1 contains 8 to 18 carbon atoms and R2 and R3 each contain 1-4 carbon atoms, alkylethercarboxylic acid surfactant in an amount of 0.1-5 wt. % alkylethercarboxylic acid surfactant wherein the alkylethercarboxylic acid surfactant is an alkylethercarboxylic acid of the formula R—O—(CH(Y)—CH2—O)n—CH2—COOH, wherein R is an alkyl or alkylene group containing 6-16 carbon atoms, and each Y is independently selected from H or CH3, n is 3-10, or a salt thereof, hydrogen peroxide in an amount of 0.1-7 wt. %, chelating agent in an amount of 0.01-2.0 wt. %, less than 15 wt. % of C1-C6 alcohol, less than 0.10 wt. % of quaternary ammonium surfactants, and less than 0.1 wt.

Abstract: A method of manufacturing an implant for use in a surgical procedure, a corresponding implant and the use thereof during the incorporation of a substance is presented. Specifically anodized and blasted titanium implant substrates are provided with a hydroxyapatite (HA) coating for incorporating for example a therapeutic agent. In particular, an anodizing procedure by an electrolytic process in an alkaline liquid is carried out. Moreover, blasting of the anodized titanium implant substrate is carried out by the presented method. The HA coating can be in the range of 1 to 5 ?m, particularly in the range of 1 to 3 ?m. A local delivery of the active pharmaceutical ingredient is achieved by the implant of the present invention. Moreover, the implant allows for the removal of the implant without damaging surrounding tissue or a bone. Moreover, the HA coating is provided to the substrate such that enhanced fixation as measured by pull-out force is achieved whilst having a relatively low removal torque.

Abstract: The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, with substantial reduction in sub-visible particles, and methods of manufacture of these compositions, methods of administration, and articles of manufacture.

Abstract: A core-shell gel particle of the invention contains a crosslinked hyaluronic acid, has a higher equilibrium swelling capacity at the surface than at the center, the equilibrium swelling capacity showing a change curve with an inflection point from the center to the surface, and has a probe pushing force of 20 nN or less from the surface to a depth of 800 nm.

Abstract: The present invention provides for metal chelating compositions which are soluble in aqueous media. The present invention also provides chelating compositions that possess acceptable iron sequestering strengths and are able to present a physical form that potentially inhibits (e.g. does not permit easy) access of iron sequestered by the compositions to the cells being targeted. Compositions comprising chelating aspects affixed to or incorporated into suitable carrier materials such that the resulting metal chelating composition is soluble in aqueous media are also provided. Disclosed herein are chelating compositions, for chelating one or more essential metals.

Abstract: The present invention relates to an injectable system combining a hydrogel, a bioceramic and a degradable matrix that provides for sustained drug delivery and structural support to recovering tissue, such as bone and the periodontium.

Abstract: Hydrodynamic methods for conformally coating non-uniform size cells and cell clusters for implantation, thus preventing immune rejection or inflammation or autoimmune destruction while preserving cell functionality. A method for conformally coating cells and c clusters with hydrogels that are biocompatible, mechanically and chemically stable and porous, with an appropriate pore cut-off size. The methods of the invention are advantageously reproducible and result in a relatively high yield of coated versus non-coated cell clusters, without compromising cell functionality. Conformal coating devices configured to perform the methods of the invention, methods of optimally utilizing said devices and purifying the coated islets, and coated biomaterials made by said methods.

Abstract: The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C24/Cmax oxycodone ratio of 0.6 to 1.0 or 0.7 to 1 after oral administration at steady state to patients and methods thereof.

Abstract: Hydrodynamic methods for conformally coating non-uniform size cells and cell clusters for implantation, thus preventing immune rejection or inflammation or autoimmune destruction while preserving cell functionality. A method for conformally coating cells and cell clusters with hydrogels that are biocompatible, mechanically and chemically stable and porous, with an appropriate pore cut-off size. The methods of the invention are advantageously reproducible and result in a relatively high yield of coated versus non-coated cell clusters, without compromising cell functionality. Conformal coating devices configured to perform the methods of the invention, methods of optimally utilizing said devices and purifying the coated islets, and coated biomaterials made by said methods.

Abstract: The present invention relates to hydrogels which may be used to encapsulate or entrap live cells. The invention further relates to methods for transporting live cells which are encapsulated or entrapped within hydrogels from a first location to a second location. The invention further relates to method of treating a wound, disease or tissue injury, e.g. an ocular injury or a damaged ocular surface in a subject using a hydrogel comprising corneal stem cells. The hydrogels used in such methods may be ones which have been transported from a first location to a second location.

Abstract: The disclosed molecules are inhibitors of Bcr-Abl and Src kinases. The molecules are cytotoxic to Gleevec resistant cells. Inhibitors of Bcr-Abl and Src kinases are used in the treatment of Chronic Myelogenous Leukemia among other diseases.

Abstract: The present invention is directed to a process for manufacturing a transdermal delivery device comprising a backing layer, a release liner, and an adhesive layer between the backing layer and release liner. More specifically, the invention is directed to a process of preparing an adhesive layer, wherein the adhesive layer is comprised of polyisobutylene and an active pharmaceutical ingredient.

Abstract: Disclosed in certain embodiments is a system and method of providing a dronabinol oral solid dosage form with increased stability.

Abstract: A composition for use in the treatment of fistula, the composition comprising activated carbon.

Abstract: The invention provides methods of treating or reducing the incidence of an infection in a mammal due to a biofilm associated infectious microorganism comprising administering a therapeutically effective amount of free available chlorine (FAC) water to a site populated with biofilm associated infectious microorganism.